A carregar...
Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC
In the REVEL trial, ramucirumab, a monoclonal antibody to VEGFR-2, improved overall survival in combination with docetaxel compared to docetaxel alone in the second-line setting of non-small cell lung cancer (NSCLC). Along with bevacizumab and nintedanib, ramucirumab is the third anti-angiogenic age...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pioneer Bioscience Publishing Company
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367672/ https://ncbi.nlm.nih.gov/pubmed/25806332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.09.05 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|